Marksans Pharma is currently trading at its intraday high point at Rs.117.50, a rise of almost 8% and not too far from its 52-week high of Rs.122.50.
There was good news from the US FDA inspection; the company announced just now that its wholly owned subsidiary Time-Cap Laboratories, Inc. has received Establishment Inspection Report (ErR) from US Food & Drugs Administration for the audit conducted in October 2023. No 483' s were issued during the Audit.
And yesterday, the company had informed that its newly acquired manufacturing facility in Verna, Goa has successfully undergone inspection from German health authorities. The Authorities have not found any critical/major observations but have minor points which the company is committed to implement.
The company, headquartered at Mumbai is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA.